Survivorship Programs Improve Quality of Life, Satisfaction in Prostate Cancer
the Cancer Therapy Advisor take:
Men with prostate cancer managed in a survivorship program report higher quality of life (QOL) and satisfaction than those who were managed by routine care, according to an article published online in Cancer.
In this study, patient-reported outcomes (PROs) such as QOL were integrated into a prostate cancer survivorship clinic and evaluated at 6 and 12 months.
Participants included 235 men being surgically treated for prostate cancer using routine follow-up care and 102 men managed in the survivorship clinic with the integrated point-of-care QOL reporting after radical prostatectomy.
Results showed that baseline QOL was comparable, but men in the survivorship groups had higher scores at 6 and 12 months than those following the routine care. For example, male patients in the survivorship clinic reported higher sexual function than those in routine care (52.2 vs 33.6 at 1 year, P<0.05).
The study suggests that disease-specific survivorship clinics with integrated QOL reporting may generate better results than clinics with routine care following cancer therapy.
Men with prostate cancer managed in a survivorship program report higher quality of life and satisfaction.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Long-term Survival From Ipilimumab/Nivolumab Combination in Metastatic Melanoma
- Lung Cancer Treatment in North America: Recent Advances and Future Promises
- Pembrolizumab Significantly Prolongs OS Compared With Chemotherapy in NSCLC
- Nivolumab Plus Chemotherapy Improves Overall Survival and Response Rate in NSCLC
- FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma, Questions Remain About Cost and Toxicity
- FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma
- Long-term Eltrombopag Improves Outcomes in Chronic Immune Thrombocytopenia
- Phase 1 Trial of Guadecitabine With Vaccine and Cyclophosphamide for Metastatic Colorectal Cancer
- Success of Adoptive Cell Therapy in ALL Could Be Applied to Myeloma
- Curative-intent Surgery for Cancer Increases Risk of New Persistent Opioid-use